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Introduction: The PIBHE study, promoted by the Spanish Liver and Kidney Association and the
Dialysis Virus Group of the Spanish Society of Nephrology, is the ﬁrst study to determine the
status of haemodialysis patients with chronic HBV infection and the immunisation against
the vaccine.
Method: The study has a national multicentre, observational, cross-sectional design and
was  carried out between January 2013 and 2014. A data collection folder was sent to all
the  nephrology departments and outpatient haemodialysis units in Spain, to be completed
based on patient medical ﬁles after informed consent. The data were recorded in a central
database.
Results: A total of 215 centres participated (15,645 patients), with an HBV prevalence of 1.03%.
HCV or HIV was present in 7.2% of the HBV(+) patients. Viral load was below 2000 IU/ml
in  80%. GOT and GPT levels were 19.1 ± 10.1 and 15.9 ± 9.6 IU/ml, respectively. Liver biopsy
was  performed in 7.1%. Antiviral treatment was prescribed in 30% and suspended in 12.5%:
entecavir (13.3%), lamivudine (10%), adefovir and tenofovir (6.7%), and interferon (3.3%). A
total of 34.5% were candidates for renal transplantation and 6.9% had not been evaluated;64.3% were followed up by a gastroenterologist; 27.2% of HBV(−) patients without immun-
isation had not been vaccinated. Fourteen different immunisation schedules had been used,
with an immunisation rate of 58.8%. Mean anti-HBs stood at 165.7 ± 297.8 mIU/ml. A total
of  72.7% of patients had received a vaccination course; 26.4%, 2 cycles; 1.0%, 3 cycles; and
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11.6%, a booster dose. A total of 28.3% had a poor response (anti-HBs 10–99 mIU/ml); 22.4%,
an  optimal response (anti-HBs 100–999 mIU/ml); and 7.9%, an excellent response (anti-HBs
≥1000 mIU/ml). Age was signiﬁcantly associated with response to vaccination; the mean
age of nonresponders was signiﬁcantly higher than patients who had a response of any
kind  (p < 0.05). The highest probability of an immune response was achieved with 4 doses
of  40 mcg of adjuvanted vaccine (OR: 7.3; 95%CI 3.4–15.7), for the same age and number of
cycles and boosters. Age, adjuvanted vaccine, dose and vaccination schedule inﬂuenced the
immune response and the anti-HBs titres reached (p < 0.05).
Conclusion: The prevalence of chronic HBV infection in haemodialysis in Spain is low and so
are  the rates of immunisation against the virus. The vaccination schedules used are very
diverse and have been observed to correlate with the immune response. It would therefore
be  necessary to establish a protocol for the most effective vaccination schedule to increase
immunisation in these patients.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Estudio  multicéntrico  espan˜ol  PIBHE:  prevalencia  e  inmunización  de  la
infección  crónica  por  el  virus  de  la  hepatitis  B  en  pacientes  en
hemodiálisis  en  Espan˜a
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Introducción: El estudio PIBHE, promovido por la Asociación Espan˜ola de Hígado y Rin˜ón y el
Grupo de Virus en Diálisis de la Sociedad Espan˜ola de Nefrología, es el primer estudio que
determina la situación de los pacientes en hemodiálisis con infección crónica por el VHB y
la  inmunización frente a la vacuna.
Método: Estudio nacional multicéntrico, observacional, de corte transversal, entre enero de
2013 y de 2014. Se envió un cuaderno de recogida de datos a todos los servicios de nefrología y
unidades extrahospitalarias de hemodiálisis de Espan˜a, para que lo cumplimentaran a partir
de  la historia clínica del paciente, tras consentimiento informado. Los datos se incluyeron
en  una base central.
Resultados: Participaron 215 centros (15.645 pacientes), con una prevalencia del VHB del
1,03%. El 7,2% de los pacientes VHB(+) estaba coinfectado por el VHC o VIH. La carga viral era
inferior a 2.000 UI/ml en el 80%. Los niveles de GOT y GPT fueron de 19,1 ± 10,1 y 15,9 ± 9,6
UI/ml, respectivamente. La biopsia hepática se había realizado en el 7,1%. El 30% había
recibido tratamiento antiviral, que se había suspendido en el 12,5%. El más empleado había
sido  entecavir (13,3%), seguido de lamivudina (10%), adefovir y tenofovir (6,7%) e interferón
(3,3%). El 34,5% era candidato a trasplante renal y el 6,9% no había sido evaluado. Se encon-
traban en seguimiento por un digestólogo el 64,3%. No había sido vacunado el 27,2% de los
pacientes VHB(−) sin inmunización. Se emplearon 14 pautas distintas de vacunación, con
un  58,8% de inmunización. La media de anti-HBs se situaba en 165,7 ± 297,8 mUI/ml. El 72,7%
de  los pacientes había recibido un ciclo de vacunación; el 26,4%, 2 ciclos; el 1,0%, 3 ciclos y
el  11,6%, una dosis de recuerdo. El 28,3% tuvo una respuesta pobre (anti-HBs 10-99 mUI/ml);
el  22,4%, una respuesta óptima (anti-HBs 100-999 mUI/ml); y el 7,9%, una respuesta exce-
lente (anti-HBs ≥ 1.000 mUI/ml). La edad se asoció signiﬁcativamente con la respuesta a la
vacunación, de manera que los pacientes que no respondieron tenían una edad media signi-
ﬁcativamente mayor que los pacientes que obtuvieron cualquier tipo de respuesta (p < 0,05).
La  mayor probabilidad de conseguir una respuesta inmunitaria se alcanzaba con 4 dosis de
40  mcg de vacuna adyuvada (OR: 7,3; IC 95%: 3,4-15,7), a igualdad de edad y número de reva-
cunaciones y recuerdos. La edad, la vacuna adyuvada, la dosis y el esquema de vacunación
inﬂuían en la respuesta inmunitaria y en el título de anti-HBs alcanzado (p < 0,05).
Conclusión: La prevalencia de la infección crónica por el VHB en hemodiálisis en Espan˜a es
baja,  así como las tasas de inmunización frente a este virus. Los esquemas de vacunación
empleados son muy diversos y se han correlacionado con la respuesta inmunitaria, por
lo  que sería necesario protocolizar la pauta más eﬁcaz para aumentar la inmunización en
estos  pacientes.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es unartículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Hepatitis B virus (HBV) infection is more  frequent in patients
with chronic renal disease (CRD) than in the general popula-
tion. In haemodialysis patients, the prevalence ranges from
0% to 10%,1 with a wide variance between the country’s
haemodialysis units. In Spain, in 2003 the prevalence of HBV
infection in haemodialysis patients was estimated to be 3.1%.1
In kidney transplant patients, the prevalence of HBV infection
was around 2%,2 also with a wide geographic and demographic
variability.
The infection by HBV in this population has decreased since
the application of prevention measures in the 1970s, and the
vaccination in 1986.
The natural history of hepatitis B in the dialysis popula-
tion is not well understood due to its slow progression, which
may be caused by numerous factors, including coinfection
with hepatitis C virus, alcohol consumption and immunosup-
pression. In kidney transplant patients, chronic hepatitis B
progresses more  aggressively than in dialysis patients; this
is due to the immunosuppression and the reduced activity
of cytotoxic T lymphocyte, which increase viral replication.3
Dialysis patients rarely present symptoms of acute hepatitis
B and their transaminase levels are usually normal or mildly
elevated during chronic infection.4,5 These differences may be
explained by uraemia, vitamin B deﬁciency and the patient’s
nutritional status. The amount of HBV(+) in dialysis patients
is usually low and stable over time.6
The main objective in the treatment chronic HBV infection
is the clearance of HBsAg and the seroconversion to anti-HBs.
However, this is only achieved in a minority of immunocom-
petent patients and is rarely seen in immunocompromised
patients. A more  realistic objective is to suppress HBV
replication efﬁciently and persistently to reduce hepatic
necroinﬂammatory activity and halt or delay ﬁbrosis progres-
sion to prevent the development of complications such as
cirrhosis, decompensation of liver function and hepatocellular
carcinoma.
HBV infection treatment indications are based on viral
load, transaminase levels and severity of liver failure. The
dosage of all drugs given to patients with chronic kidney dis-
ease (CKD) must be adjusted and has to be administered with
caution, serum creatinine and, in some cases, serum phos-
phorus levels should be monitorized. The use of interferon is
contraindicated in kidney transplant patients due to risk of
rejection.
Universal vaccination of CKD patients, patients on dialy-
sis and healthcare professionals are recommended. The most
recommended regimen is the double dose (40 mcg) of the
conventional vaccine (Engerix®, HBvaxPRO®) at 0, 1, 2 and 6
months.7 The immunity rates of haemodialysis patients vac-
cinated against HBV range from 40% to 70%, compared to
97% for the general population,8 with a subsequent progres-
sive loss of immunisation that increases with time. Various
adjuvants were studied to improve the immunisation in
speciﬁc populations (granulocyte and macrophage colony-
stimulating factor, interleukin-2, interferon, thymopentin),9,10
until a vaccine containing 3-O-desacyl-40-monophosphoryl
lipid A was developed. A clinical trial by Tong et al.11;3 6(2):126–132
compared immunisation with the conventional double-dose
vaccine against the single-dose adjuvanted vaccine (Fendrix®)
at 0, 1, 2 and 6 months, ﬁnding immunity rates of 84%
versus 91%. A number of factors affect the response to
HBV vaccination: anaemia, malnutrition,12–14 weight, male
gender,15,16 renal function, secondary hyperparathyroidism,
reduced immunoglobulin production, loss of interleukin-2 by
T lymphocytes, macrophage dysfunction and high levels of
indoleamine 2,3-dioxygenase.17
It is important to develop strategy for HBV infection pre-
vention and management in the CRD population because of
their high exposure to blood or blood-derived products, fre-
quent venipuncture, invasive procedures, medical equipment
and healthcare personnel.
There is lack of data in the medical literature concern-
ing evaluation and monitoring of chronic hepatitis B in
haemodialysis patients and the level of immunisation and the
vaccination in patients without hepatitis B. Thus we  believe it
was necessary to conduct a cross-sectional study to encom-
pass all associated aspects and to detect improvements in
disease management, as well as multidisciplinary interven-
tion with nephrologists and hepatologists. This study, spon-
sored by the Spanish Liver and Kidney Association (AEHR) and
the Dialysis Virus Group of the Spanish Society of Nephrology
(SEN), is the ﬁrst of its kind to incorporate the following objec-
tives: (1) to determine the prevalence of chronic HBV infection
in CRD patients undergoing renal replacement therapy with
haemodialysis in Spain, and to evaluate liver disease-related
aspects and their status in regard with kidney transplant; (2)
to gain information about the immunisation against HBV in
this population and the associated response factors.
Method
A formulary comprising the study variables to be completed
for every haemodialysis patient using their medical records.
This was sent together with a cover letter via regular mail and
also by email to every nephrology department and every out-
patient haemodialysis unit in Spain. This was, followed by a
telephone call to conﬁrm the reception of the documentation.
This procedure was repeated 6 months later in those sites that
did not respond. The case report form had to be completed by
a local investigator from each site and be returned by postmail
to the coordinating site, or by email to the study coordinator
group. Then, the data was entered into a central database.
Patients who had not previously granted their authorisa-
tion for the use of their data in scientiﬁc research, stored by the
healthcare site in question, had to sign an informed consent
to authorise the use of their data.
The study was approved by the Independent Ethics Com-
mittee of the coordinating site, Hospital La Mancha-Centro in
Alcázar de San Juan (Ciudad Real), Spain.
Data collection was conducted from January 2013 to Jan-
uary 2014, followed by centralisation and analysis.• Site
• Number of patients at the site, number of HBV(+) patients
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 Investigator
 Date
 HBV(+) patients
◦ Patient’s initials
◦ Age
◦ HCV/HIV coinfection (yes/no)
◦ Viral load
◦ GOT/GPT
◦ GGT
 Liver biopsy (yes/no, description)
◦ Previous HBV treatment (interferon, lamivudine, ente-
cavir, tenofovir, adefovir, others)
◦ Treatment duration
◦ Dose
◦ Discontinuation (yes/no, cause)
◦ Candidate for kidney transplant (yes/no/not evaluated,
refused by the patient)
◦ Follow-up by the Gastrontestinal (GI) service (yes/no) HBV(−) patients
◦ Serology: anti-HBs antibodies, anti-HBc antibodies
◦ HBV vaccination (yes/no)
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Type of vaccine (Engerix®, Fendrix®)
Regimen (0-1-6, 0-1-2-6, other)
Dose
Booster (yes/no), type of vaccine, regimen, dose
• Did this questionnaire help you to assess HBV infection
management in your unit? (yes/no)
Statistical  analysis
Measurement of central tendency (mean and median) was
used to describe the quantitative variables, together with
measures of dispersion (standard deviation or interquartile
range), depending on normal distribution. The qualitative
variables were described by their absolute and relative fre-
quencies.
The chi-square test and Student’s t-test were used to com-
pare qualitative variables, and the Mann–Whitney U test was
used to compare the means of quantitative variables. A multi-
variate logistic regression model was used to assess the asso-
ciation between immunisation and the different therapeutic
regimens. p < 0.05 was considered to be statistically signiﬁcant.
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Table 1 – Vaccination regimens.
Vaccine Dose in mcg Administration
Conventional 10 0, 1, 2, 6
Conventional 10 Other
Conventional 10 0, 1, 6
Conventional 10 0, 1, 2, 6
Conventional 10 Other
Conventional 40 0, 1, 6
Conventional 40 0, 1, 2, 6
Conventional 40 Other
Adjuvanted 20 0, 1, 6
Adjuvanted 20 0, 1, 2, 6
Adjuvanted 20 Other
Adjuvanted 40 0, 1, 6130  n e f r o l o g i a. 2
The data were analysed using version 18.0 of the SPSS pro-
gram.
Results
Data  of  the  participating  sites
Out of the 366 haemodialysis units in Spain, 215 (59%) par-
ticipated in the study. 53.7% of the participating units were
at hospitals. All units sent their prevalence data and 42 sent
the completed case report form. Fig. 1 shows the participation
distributed by autonomous region.
One hundred and sixty-two out of the 15,645 registered
patients were HBV(+), so the prevalence of hepatitis B is 1.03%.
Based on the sample surveyed, 64.2% of sites had at least one
HBV(+) patient.
Case report forms for 2187 patients were received.
Information  about  HBV(+)  patients
HBV(+) patients had a mean age of 50 ± 14.6 years, ranging
from 26 to 66 years.
7.2% were coinfected with hepatitis C virus or human
immunodeﬁciency virus (HIV). 19.2% had anti-HBe antibodies
and this had not been evaluated in 3.8% of cases. Viral quan-
tiﬁcation was below 2000 IU/ml in 80% of patients. GOT and
GPT levels were 19.1 ± 10.1 and 15.9 ± 9.6 IU/ml, respectively.
7.1% of patients had undergone liver biopsy.
30% of patients had received antiviral treatment, which
was suspended in 12.5% of cases. The most-prescribed antivi-
ral was entecavir (13.3%), followed by lamivudine (10%),
adefovir and tenofovir (both 6.7%), interferon (3.3%) and others
(3%).
34.5% of patients were candidates for kidney transplant
and 6.9% had not been evaluated. 64.3% were being followed
up by a gastroenterologist.
Information  on  HBV(−)  patients
HBV(−) patients had a mean age of 66.8 ± 14.9 years, ranging
from of 19 to 100 years.
A 27.2% of patients without immunisation had not been
vaccinated; 17.9% of patients had anti-HBc antibodies, and
66.1% of these had not been vaccinated. Fourteen different
vaccination regimens were used; these are shown in Table 1.
A 58.8% of vaccinated patients were successfully immunised.
Mean of anti-HBs was 165.7 ± 297.8 mIU/ml (0–1000).
Type  of  vaccine  and  vaccination  cycles
In 23% of patients the type vaccine administered was not doc-
umented. Engerix® was administered to 52.3% of patients,
followed by Fendrix® in 26.9% and HBvaxPRO® in 20.9%.
72.7% of patients received one vaccination cycle; 26.4%
received 2 cycles; 1.0%, 3 cycles; and 11.6% of patients were
given a booster. The immunisation relative to the number of
cycles was 80% with one cycle, 19.5% with 2 cycles and 0.5%
with 3 cycles.
The most used booster vaccination was Engerix® (39.3%)
followed by Fendrix® (32.5%) and HBvaxPRO® (24.0%). The typeAdjuvanted 40 0, 1, 2, 6
Adjuvanted 80 Other
of booster vaccination administered was unknown in 3.3% of
patients.
Vaccination  response
A 41.4% of patients did not respond to the vaccination. A 28.3%
had a poor response (anti-HBs 10–99 mIU/ml); A 22.4% had an
optimal response (anti-HBs 100–999 mIU/ml); and 7.9% had an
excellent response (anti-HBs ≥1000 mIU/ml).
Age was signiﬁcantly associated with response to vaccina-
tion; the mean age of non-responders was signiﬁcantly higher
than patients who had a response of any kind (p < 0.05) (Fig. 2).
The highest likelihood of achieving an immune response
was obtained with 4 doses of 40 mcg  of adjuvanted vaccine
(OR: 7.3; 95%CI: 3.4–15.7), for the same age and number of
cycles and boosters. Age, adjuvanted vaccine, dose and vac-
cination regimen inﬂuenced the immune response and the
anti-HBs titres achieved (p < 0.05).
Questionnaire  self-assessment
A 78% of the representative investigators from each site
deemed the questionnaire to have been helpful in assessing
patient management at their unit. Regarding to HBV infec-
tion and immunisation, a 17.1% did not ﬁnd the questionnaire
useful and 4.9% did not answer.
Discussion
Data from the present study reveals that the prevalence of
chronic hepatitis B in haemodialysis patients in Spain to
be 1.03%, a value lower than the 3.1% estimated by Burdick
et al. in the 2003 DOPPS study.1 This reduction in the preva-
lence of HBV in haemodialysis patients in Spain could be
due to numerous reasons, including the death of patients
infected by contaminated transfusions prior to the 1990s and
the preventive measures implemented by the haemodialysis
units including isolation and vaccination. The DOPPS study
included 308 sites but only 20 were from Spain; this is in con-
trast to the 215 sites recruited to the PIBHE study, which was
not free of sampling bias given that HBV(+) patients are more
centralised than HCV(+). This is evidenced by the fact that
64.5% of sites had at least one HBV(+) patient, versus 75.9% of
sites with HCV(+), as shown reﬂected in the SHECTS study.18
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Patients with HBV(+) were younger than HBV(−) patients,
ith a mean age of 50 ± 14.6 versus 66.8 ± 14.9 years, respec-
ively, which may be related to shorter life expectancy due
o the infection. Although no HBV morbidity/mortality stud-
es in CKD or dialysis patients have been conducted to date.
n HBV + kidney transplant patients, mortality at 10 and 20
ears is 85% and 71%, respectively versus 98% and 95% in
BV(−) transplant patients, despite antiviral treatment.19 A
eta-analysis by Fabrizi et al.20 found that the post-transplant
ortality risk of kidney transplant patients with HBV infection
s 2.49 times greater than for non infected patients.
Liver biopsy is not widely used (7.1%). This may be due to
he increased risk of bleeding in kidney patients and also the
evelopment of the elastography, although this technique has
et to be validated in this population.
The nephrotoxicity associated with tenofovir and adefovir
ay explain the greater use of entecavir and lamivudine, as
eﬂected in the antiviral prescription data. One of the reasons
hy antivirals were prescribed in only 30% of patients may be
ecause of to the situation of inactive carriers of HBV, with low
iral replication and normal transaminase levels.
Although this study shows that most HBV(+) patients are
ssessed for kidney transplant, it is not known why the pro-
ortion of candidates is low (34.5%).
Follow-up of all patients by a gastroenterologist is advisable
iven the risk of HBV reactivation and hepatocellular carci-
oma. However, this study suggests that such follow-up only
ccurs in 64.3% of cases.
With  respect to the HBV(−) patients, it is of note that
3% had not been vaccinated, despite the fact that the clin-
cal guidelines recommend vaccination for all haemodialysis
atients.
A 17.3% of patients have anti-HBc antibodies, but a con-
iderable proportion lack immunisation and have not beenaccination response.
vaccinated (33.8%); these patients are also more  likely to
achieve immunity by immunological memory,  and thus are
at greater risk of reactivation in the event of immunosuppres-
sion, making vaccination even more  necessary.
The overall number of immunised haemodialysis patients
is 61.9%, similar to previous studies, 68.7% in the study
conducted by Siddiqui et al.,21 with 40 mcg  of conventional
vaccine, although the wide variety of vaccination regimens
used (up to 14) and the limited use of a second cycle (21.5%)
suggests that better immunological response may be achieved
with more  effective regimens. This strategy has already been
tested in other studies, rescuing a large number of patients
with a second cycle of conventional vaccine and a third cycle
with adjuvanted vaccine.22 The second vaccination cycle in
the PIBHE study rescued 19.5% of non-responders. Despite that
the clinical practice guidelines are not totally clear in terms
of vaccination and booster protocols, there is consensus on
the need to double the conventional vaccine dose.23 Of  note,
there are vaccination regimens with 10 mcg, these are dose
used in children, and with 20 mcg, as well as adjuvanted vac-
cine doses of 40 and 80 mcg, which to date have never been
tested in clinical trials or controlled tests.
The positive assessment of most nephrologists (78%)
regarding the usefulness of this questionnaire suggests the
need to develop similar strategies to perform self-assessment
of patient management and to adopt an interventionist
approach.
This is the ﬁrst study in the world that has been designed
to assess the level of valuation and follow-up of HBV(+)
patients and the vaccination and immunisation of HBV(−)
haemodialysis patients. It highlights the fall in prevalence of
HBV in haemodialysis patients in Spain over 10 years and
the wide range of vaccination regimens together with the
low immunisation rates, with a potential for improvement
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with the development of better strategies. A multidisciplinary
approach including nephrologists and hepatologists would be
necessary, together with an update clinical practice guidelines
in terms of HBV vaccination in haemodialysis patients.
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Appendix  A.  Supplementary  data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.nefroe.2016.04.004.
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